ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Resveratrol-mediated disruption of the CD73-adenosine-A2AR/A2BR axis induces antitumor activity in colon cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Conventional therapeutic approaches against colorectal cancer often face limitations. One of the critical pathways implicated in tumor progression is the adenosinergic signaling pathway, which plays a major role in immune suppression within the tumor microenvironment. This investigation aimed to evaluate the effect of resveratrol on adenosine production and its antitumor potential in colon cancer cell lines (CT26 and SW480) under in vitro conditions. In this experimental investigation, human (SW480) and murine (CT26) colon cancer cell lines were subjected to various concentrations of resveratrol to assess its biological impacts. Apoptosis and MTT assays were performed to evaluate cell viability, while quantitative real-time PCR was used to measure the expression levels of A2AR, A2BR, and 5'-nucleotidase (CD73) genes. AMP hydrolysis was conducted for CD73 activity assay. Additionally, the impact of resveratrol on the migratory capacity of the cells was determined by scratch assay. A distinct decline in cell survival was observed with increasing resveratrol concentrations, accompanied by a corresponding rise in apoptotic activity in both CT26 and SW480 cells with IC50 value of 54.2 and 23.2 μM, respectively. In addition, wound closure rates in the scratch assay were markedly decreased following resveratrol exposure, indicating inhibition of cell migration. CD73 enzymatic activity and expression were significantly downregulated, leading to reduced adenosine production. Furthermore, resveratrol dose-dependently inhibited the expression of A2AR and A2BR, suggesting disruption of the adenosinergic signaling pathway. These findings designate that resveratrol has a strong inhibitory effect on colon cancer cells by inhibiting CD73-mediated adenosine production and downregulating adenosine receptor expression.
Indexed as
Identifiers
42053794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.